Trileptal 150 mg Норвегия - норвежский - Statens legemiddelverk

trileptal 150 mg

novartis norge (2) - okskarbazepin - tablett, filmdrasjert - 150 mg

Trileptal 300 mg Норвегия - норвежский - Statens legemiddelverk

trileptal 300 mg

novartis norge (2) - okskarbazepin - tablett, filmdrasjert - 300 mg

Trileptal 600 mg Норвегия - норвежский - Statens legemiddelverk

trileptal 600 mg

novartis norge (2) - okskarbazepin - tablett, filmdrasjert - 600 mg

Zyvoxid 600 mg Норвегия - норвежский - Statens legemiddelverk

zyvoxid 600 mg

pfizer as - linezolid - tablett, filmdrasjert - 600 mg

Linezolid Krka 600 mg Норвегия - норвежский - Statens legemiddelverk

linezolid krka 600 mg

krka, d.d. novo mesto - linezolid - tablett, filmdrasjert - 600 mg

Mykofenolsyre Accord 180 mg Норвегия - норвежский - Statens legemiddelverk

mykofenolsyre accord 180 mg

accord healthcare b.v. - mykofenolatnatrium - enterotablett - 180 mg

Mometason Glenmark 1 mg/ g Норвегия - норвежский - Statens legemiddelverk

mometason glenmark 1 mg/ g

glenmark arzneimittel gmbh - mometasonfuroat - krem - 1 mg/ g

Linezolid Accord 2 mg/ ml Норвегия - норвежский - Statens legemiddelverk

linezolid accord 2 mg/ ml

accord healthcare b.v. - linezolid - infusjonsvæske, oppløsning - 2 mg/ ml

Dimethyl fumarate Polpharma Европейский союз - норвежский - EMA (European Medicines Agency)

dimethyl fumarate polpharma

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimetylfumarat - multippel sklerose, relapsing-remitting - immunsuppressive - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Celdoxome pegylated liposomal Европейский союз - норвежский - EMA (European Medicines Agency)

celdoxome pegylated liposomal

yes pharmaceutical development services gmbh - doxorubicin hydroklorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastiske midler - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).